News
To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...
Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...
Our federal lawmakers should substantial and sustained investments for Alzheimer’s research funding and the dementia public ...
3d
GlobalData on MSNEli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costsNICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...
In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...
To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...
TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...
2d
Zacks.com on MSNLLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
A newly approved Alzheimer’s drug is set to be administered for the first time in Taiwan on Monday, Far Eastern Memorial Hospital in New Taipei City announced yesterday. Kisunla, the brand name of the ...
However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...
And other biotech news brought to you by The Readout.
Microsoft co-founder Bill Gates reflects on his father's Alzheimer's battle and expresses optimism about advancements in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results